1. Home
  2. CNMD vs URGN Comparison

CNMD vs URGN Comparison

Compare CNMD & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CONMED Corporation

CNMD

CONMED Corporation

HOLD

Current Price

$39.96

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$24.62

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNMD
URGN
Founded
1970
2004
Country
United States
United States
Employees
N/A
291
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.1B
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
CNMD
URGN
Price
$39.96
$24.62
Analyst Decision
Hold
Strong Buy
Analyst Count
6
7
Target Price
$48.00
$29.29
AVG Volume (30 Days)
356.4K
649.8K
Earning Date
04-29-2026
05-11-2026
Dividend Yield
1.02%
N/A
EPS Growth
N/A
N/A
EPS
1.51
N/A
Revenue
$1,374,724,000.00
$1,128,000.00
Revenue This Year
$0.82
$127.17
Revenue Next Year
$5.48
$73.82
P/E Ratio
$25.89
N/A
Revenue Growth
5.18
N/A
52 Week Low
$33.21
$3.42
52 Week High
$60.80
$30.00

Technical Indicators

Market Signals
Indicator
CNMD
URGN
Relative Strength Index (RSI) 58.75 72.75
Support Level $39.36 $18.55
Resistance Level $46.08 $30.00
Average True Range (ATR) 1.46 1.28
MACD 0.65 0.61
Stochastic Oscillator 93.47 99.73

Price Performance

Historical Comparison
CNMD
URGN

About CNMD CONMED Corporation

Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: